Equity Overview
Price & Market Data
Price: $65.06
Daily Change: +$0.55 / 0.85%
Daily Range: $63.74 - $65.07
Market Cap: $4,047,468,288
Daily Volume: 529,977
Performance Metrics
1 Week: 11.04%
1 Month: 13.19%
3 Months: 21.20%
6 Months: 23.85%
1 Year: 41.68%
YTD: 68.55%
Company Details
Employees: 126
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.